Analysis of ratios
-
Upload
arannya-chowdhury -
Category
Economy & Finance
-
view
340 -
download
0
Transcript of Analysis of ratios
REPORT ON FINANCIAL STRUCTURE
OFRENATA LTD & SQUARE PHARMACEUTICALS LTD.
1
Prepared For:
SHANILA TANEEM (SNT)
Prepared by:
SUMAIYA KHAN ANHA - 1510260030
ALI ARFI SHAFAT CHOWDHURY - 1510376630
TARANNUM HAIDER MALIHA - 1511332630
DIPANNITA FARHAHA INITA - 1110533030
NAFIS JAWAD RAHMAN - 1311015630
Table of Contents2
No. Contents Page Number
1 Description of Company 04
2 Solvency measures 05-13
3 Recommendation 14
4 Conclusion 14
Brief description of the companies:Renata LTD:
Renata Limited (formerly Pfizer Laboratories (Bangladesh) Limited), also known as Renata, is one of the top ten (in terms of revenue).Renata is engaged in the manufacture and marketing of human pharmaceutical and
3
animal health products. The company also manufactures animal therapeutics and nutrition products.The company began its operations as Pfizer (Bangladesh) Limited in 1972. For the next two decades it continued as a subsidiary of Pfizer Corporation However, by the late 1990s the focus of Pfizer had shifted from formulations to research. In accordance with this transformation, Pfizer divested its interests in many countries, including Bangladesh. Specifically, in 1993 Pfizer transferred the ownership of its Bangladesh operations to local shareholders, and the name of the company was changed to Renata Limited. At present, Renata manufactures about 300 generic pharmaceutical products including hormones, contraceptives, anti-cancer drugs, oral preparations, cephalosporins, parenteral preparations as well as other conventional drugs. In addition, they also offer about 95 animal therapeutics and nutrition products.
Square Pharmaceuticals LTD:The company was founded in 1958 by Samson H.Chowdhury along with three of his friends as a private firm. It went public in 1991 and is currently listed on the Dhaka Stock Exchange. Square Pharmaceuticals Ltd., the flagship company, is holding the strong leadership position in the pharmaceutical industry of Bangladesh since 1985 and it has been continuously in the 1st position among all national and multinational companies since 1985. Square Pharmaceuticals Ltd. is now on its way to becoming a high performance global player. As per vision, mission and objectives; they are to emphasize on the quality of product, process and services leading to growth of the company imbibed with good governance.
Solvency MeasuresLiquidity ratios
Current ratio means the firm’s ability to meet its short-term obligations. Current ratio is always good when it is higher than 1 times.
‘
4
2011 2012 2013 20140
0.5
1
1.5
2
2.5
RENATA LTDSQUARE PHARMA-CEUTICALS LTDINDUSTRY AVERAGE
Square Pharmaceuticals LTD. is operating above the industry average whereas Renata LTD is operating below the industry average. As a result, the current ratio of Square is above 2, which is very good as it has the capacity to pay off its liability.
Quick ratio is similar to current ratio, except that it excludes inventory, which is generally the least liquid current asset. Quick ratio is also good when it is greater than 1 times.
2011 2012 2013 20140
0.20.40.60.8
11.21.41.61.8
RENATA LTDSQUARE PHARMACEU-TICALS LTDINDUSTRY AVERAGE
Square Pharmaceuticals Ltd. has a fluctuating graph whereas it is still operating above the industry average. Despite of it, the quick ratio is falling below 1. On the contrary, Renata Ltd. has a very low quick ratio of 0.5 in 2014. However, it faced its trough in year 2013 when it had a quick ratio of below 0.5.
Activity ratios
Inventory turnover means the activity, or liquidity of a firm’s inventory. The higher the inventory turnover is, the better it is.
5
Current ratio
Quick ratio
2011 2012 2013 20140
1
2
3
4
5
6
RENATA LTD.SQUARE PHAR-MACEUTICALS LTD.INDUSTRY AVERAGE
The inventory turnover of square is above the industry average not only that it is still rising till date. It reached the peak in 2014 with an inventory turnover of 5 times. On the contrary, Renata has an inventory turnover below industry average and faced an all time low in around 2013.
Avg. age of inventory means how many times are being used to sell the product. The lower the avg. age of inventory turnover is, the better it is.
2011 2012 2013 20140
50
100
150
200
250
RENATA LTDSQUARE PHARMA-CEUTICALS LTDINDUSTRY AVERAGE
From the graph, we can depict that Square is in a better position than Renata as it has a value below industry average. Moreover, Renatahas a very high average age of inventory. Therefore in this particular case also square is performing better than Renata.
Avg. collection period means the approximate amount of time that it takes for a business to receive payments owed. Every company wants to sell their products faster and get the payment faster. So the lower the avg. collection period is, the better it is.
6
Inventory turnover
Avg.age of inventory
2011 2012 2013 20140
10203040506070
RENATA LTDSQUARE PHARMA-CEUTICALS LTDINDUSTRY AVERAGE
According to the graph, Renata LTD. has an upward sloping graph which means it takes a lot of time to receive payments from its accounts receivables. Whilst, Square has a very low avg. collection period and has faced a downfall in 2014 with almost a value of 10.
Total asset turnover (T.A.T.O) means the efficiency with which the firm uses its assets to generate sales. The higher the T.A.T.O. is, the better it is.
2011 2012 2013 20140
0.10.20.30.40.50.60.70.80.9
1
RENATA LTDSQUARE PHARMACEU-TICALS LTDINDUSTRY AVERAGE
The graph illustrates two scenarios of Renata and Square-
1) Renata was operating above the industry average and Square was below the industry average from 2011 to somewhere around 2012.
2) After 2012, Square started operating above the industry average and Renata faced a trough at its worst in 2013 with almost a value of 0.69.
As a result, from this particular graph we can assume Square is performing better than Renata and is using its assets more efficiently.
Debt. RatiosDebt. Ratio means the proportion of total assets financed by the firm’s creditors. We know that, the lower the debt. Ratio is, the better it is.
7
Avg. collection period
Total asset turnover
2011 2012 2013 20140.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
RENATA LTDSQUARE PHARMA-CEUTICALS LTDINDUSTRY AVERAGE
From the debt ratio graph, we can measure that the debt. ratio of the both industries has gone downwards. It means both of the industries have lower capital financed from debts. However, Square has a lower debt ratio of 16% in 2014 in comparison to Renata Ltd. which is 35.98%. Moreover, Renata is also operating above the industry average for the last 4 years.
Debt. To equity ratio means the relative proportion of total liabilities to common stock equity used to finance the firm’s assets. The lower the debt. to equity ratio is, the better it is.
2011 2012 2013 20140.00%
10.00%20.00%30.00%40.00%50.00%60.00%70.00%80.00%90.00%
100.00%
RENATA LTDSQUARE PHARMA-CEUTICALS LTDINDUSTRY AVERAGE
The graph shows that Square is performing well below the industry average whereas REnata has a ratio above the industry average. It shows that Renata is not performing well, as the lower the rate is, the better it is.
The times interest earned ratio (TIE) means the firm’s ability to make contractual interest payments. It is better for the firm when the ratio is higher.
8
Debt. ratio
Debt. To equity ratio
2011 2012 2013 201405
101520253035
RENATA LTDSQUARE PHAR-MACEUTICALS LTDINDUSTRY AVERAGE
The graph shows that square has been fluctuating in this case a lot in the last 4 years in contrast to Renata which had a relatively stable graph. However, Renata has a ratio below the industry average and hence increment in terms of this ratio is necessary. Despite of this, Square’s effort should be applauded because even after the fall in 2012 it still managed to raise a high of 29.6 times.
Profitability ratiosThe gross profit margin (G.P.M) means the percentage of each sales dollar remaining after the firm has paid for its goods. The higher the gross profit is, the better it is.
2011 2012 2013 20140.00%
100.00%
200.00%
300.00%
400.00%
500.00%
600.00%
RENATA LTD
SQUARE PHAR-MACEUTICALS LTD
INDUSTRY AV-ERAGE
The GPM graph is showing that the industry has got an upward sloping curve. Renata’s curve though looks almost the same, it has gone little downfrom 52.46% to 51.21% in the given years. On the contrary, Square was operating above the industry average till the end of 2012. However, in 2013 it faced its worst trough which might be due to higher cost of goods sold. Despite of all these fluctuations, Square did manage to increase its profit all over again by 2014.
The operating profit margin (O.P.M) measures the operational efficiency. The higher the O.P.M. is, the better it is.
9
Times interest earned ratio
Gross profit margin
2011 2012 2013 20140.00%5.00%
10.00%15.00%20.00%25.00%30.00%35.00%40.00%
RENATA LTDSQUARE PHARMA-CEUTICALSINDUSTRY AVERAGE
The OPM graph shows that the industry average has fluctuated a bit in the last 4 years. Renata has been operating above the industry average for almost 80% in the last 4 years which proves it has lower expenses than Square. Square had a very high OPM of 34.34% in 2012. In spite of the high OPM which it could not sustain, it faced a downfall in 2013.
The net profit margin (N.P.M) measures the percentage of each sales dollar remaining after all costs and expenses, including interest, taxes, and preferred stock dividends, have been deducted. Like the GPM and OPM, the upward slope is better for NPM.
2011 2012 2013 20140.00%
5.00%
10.00%
15.00%
20.00%
25.00%
RENATA LTDSQUARE PHARMA-CEUTICALS LTDINDUSTRY AVERAGE
The NPM of Renata LTD. was very high and above the industry average from 2011 to 2012 whilst Square had relatively same margin from 16.30% to 16.6%. In spite of all these factors, Renata faced a downfall in 2012 and went below the industry average in the next 2 years.
The earnings per share (EPS) of a company is generally of interest to present or prospective stockholders and management. The higher the ratio is, the better it is.
10
Net profit margin
Operating profit margin
2011 2012 2013 20140.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
RENATA LTDSQUARE PHARMACEU-TICALS LTDINDUSTRY AVERAGE
From the graph we can depict that, Renata has an EPS above the industry average in 2014 with almost 40%. On the contrary, Square had EPS below the industry average which started from 9.56% to a lower value of 7.10%. EPS is very important for the company as it will help them to gain investors.
The company’s return on assets (ROA) means the overall effectiveness of management in generating profits with its available assets. The higher the ROA is, the better it is.
2011 2012 2013 20140.00%2.00%4.00%6.00%8.00%
10.00%12.00%14.00%16.00%18.00%20.00%
RENATA LTDSQUARE PHARMA-CEUTICALS LTDINDUSTRY AVERAGE
The ROA graph shows that Renata had a very high ROA of 18.71% which was well above the industry average in 2011. However, it reduced to 15.18% in the end with the worst fall in 2013 with a value of 10.93%. Square, on the other hand, started with a low value in 2011 well below the industry average and increased to 15.18% above the industry average.
The company’s return on equity (ROE) means the return earned on the common stockholders’ investment in the firm. The higher the ROE is, the better it is.
11
Earnings per share
Return on assets
2011 2012 2013 20140.00%5.00%
10.00%15.00%20.00%25.00%30.00%35.00%40.00%
RENATA LTDSQUARE PHARMA-CEUTICALS LTDINDUSTRY AVERAGE
The ROE curve implies that Renata started off with a very high ROE of 36.35% in 2011 and ended with 22.07% in 2014. However, it was still above the industry average. On the contrary, Square had a ROE of 18.32% in 2011 which was well below industry average. It faced the worst downfall in 2012 with 15.15% and ended with 18.09% in 2014.
Market Ratios
The price/earnings ratio (P/E) measures one can analyze the market's stock valuation of a company and its shares relative to the income the company is actually generating. The higher the ratio is, the better it is.
There can be two scenarios: 1) If the share price is high and EPS is low. This shows that the stock is undervalued. They are bubble stocks and will eventually fall in the short run.
2) If both the share price and EPS is high. Although, the change is share price is higher.
2011 2012 2013 20140
1020304050607080
RENATA LTDSQUARE PHARMACEU-TICALS LTDINDUSTRY AVERAGE
From the graph we can say that Square is operating below the industry average and Renata is operating above the industry average with its peak in 2012 by 67.59%.
The Book value per share (BVPS) compares the amount of stockholders' equity to the number of shares outstanding. The higher the BVPS is, the better it is.
12
Return on equity
Price-earnings ratio
2011 2012 2013 20140
20406080
100120140160180200
RENATA LTDSQUARE PHARMA-CEUTICALS LTDINDUSTRY AVERAGE
Renata has a higher book value per share which shows that people will have more confidence on the business. On the other hand, Square has lost some confidence from the people as they have got a downfall in 2013.
The market/book ratio (M/B) is used to find the value of a company by comparing the book value of a firm to its market value. Book value is calculated by looking at the firm's historical cost, or accounting value. Market value is determined in the stock market through its market capitalization. The higher the ratio is, the better it is.
2011 2012 2013 20140
20406080
100120140160180200
RENATA LTDSQUARE PHARMACEU-TICALS LTD.INDUSTRY AVERAGE
According to the graph, The M/B ratio of Renata is very high compared to Square. Renata faced a peak in 2012 and so did Square. As a result it shows that the industry has also fluctuated.
Recommendation
From the entire report of Square Pharmaceuticals LTD. and Renata LTD. we can assume that Square is performing better than Renata in terms profitably, liquidity and debt ratio. However, in case of the P/E ratio, Square has a lower P/E than Renata. In our opinion, we would suggest investing in Square as the profits are higher and the upward trend is more
13
Book value per share
Market/Book ratio
sustainable than Renata LTD. Square has managed to perform well in almost all the sectors and dealt with their inefficiency efficiently. As a result, we believe investing in Square would have lower risk involved in comparison to the return.
Conclusion
After checking all the ratios of both the companies, we can conclude that both the companies are performing well and have their own share of respect in the market. Despite of all these, Renata has been underperforming in comparison to Square in almost all the aspect. On the contrary, Renata did manage to provide with a higher EPS than Square which might instigate investors to invest more due to higher return. But if we look at the long run prospective, Square has been outperforming Renata with better efficiency and will be a more sustainable one to invest.
Appendix
Liquidity Ratios
Renata Ltd.
14
Year Current ratio = Current assets/Current liabilities
Quick ratio = (Current assets – Inventory)/ Current liabilities
2011 2,464,125,653/3,385,850,284= 0.73 times (2,464,125,653-1,585,100,179) / 3,385,850,284= 0.26 times
2012 3,310,220,716/2,876,857,184 = 1.15 times (3,310,220,716-1,986,744,883)/ 2,876,857,184 = 0.46 times
2013 4,137,379,000/5,266,051,481 = 0.79 times (4,137,379,000– 2,628,838,384)/ 5,266,051,481 = 0.29 times
2014 5,296,370,085/5,214,178,551 = 1.02 times (5,296,370,085 – 2,760,765,470)/ 5,214,178,551 = 0.49 times
Square Pharmaceuticals Ltd.
Year Current ratio = Current assets/Current liabilities
Quick ratio = (Current assets – Inventory)/ Current liabilities
2011 7,022,213,840 /4,668,189,426 =1.5 times (7,022,213,840-2,541,688,329) /4,668,189,426 = 0.96 times
2012 8,248,571,022/4,315,390,359 = 1.91 times (8,248,571,022-3,178,672,614)/ 4,315,390,359 = 1.17 times
2013 7,768,068,298/3,416,619,593 = 1.58 times (7,768,068,298-2,345,389,488)/3,416,619,593 = 1.59 times
2014 5,996,697,544/3,792,438,255 = 2.27 times (5,996,697,544-2,503,683,240)/3,416,619,593 = 0.92 times
Activity ratiosRenata Ltd.
Year Inventory turnover = C.O.G.S/Inventory
Avg. age of inventory =
365/Inventory turnover
Avg. collection period = Accounts
receivable/Avg. sales per day
= Accounts receivable/ (Annual sales/365
Total asset turnover = Sales/Total assets
2011 3,099,355,95 365/1.95 = 187.18 640,195,291/ 6,519,639,234/7,691,601,900
15
5/1,585,100,179 = 1.95 times
days (6,519,639,234/365) = 35.84 days
= 0.85
2012 3,619,613,644/1,986,744,583 = 1.82
times
365/1.82 = 200 days 843,231,267/ (7,671,572,303/365) = 40.12
days
7,671,572,303/9,753,077,971 = 0.79
2013 4,086,775,028/2,628,838,384 = 1.55 times
365 / 1.55 = 235.48 days
877,700,564/ (8,757,405,748/365) = 36.58
days
8,757,405,748/12,714,843,610 = 0.69
2014 5,418,971,406/2,760,765,470 = 1.96 times
365 / 1.96 = 186.22 days
1,926,360,804/ (11,107,281,260/365) =
63.30 days
11,107,281,260/14,493,568,729 = 0.76
Square Pharmaceuticals Ltd.
Year Inventory turnover = C.O.G.S/Inventory
Avg. age of inventory =
365/Inventory turnover
Avg. collection period = Accounts
receivable/Avg. sales per day
= Accounts receivable/ (Annual sales/365
Total asset turnover = Sales/Total assets
2011 7,703,661,010 /2,541,688,329 =3.03 times
365 /3.03 = 120.46days
772,421,345 / (15,576,487,536/365)
=18.1days
15,576,487,536 /19,444,409,654 =0.8 times
2012 9,167,253,620 / 3,178,672,614=2.88 times
365 / 2.88 = 126.73 days
785,203,495 / (18,592,856,236 / 365) =
15.41 days
18,592,856,236 / 24,376,715,644 = 0.76 times
2013 10,133,675,177/2,503,683,240 = 4.05 times
365 / 4.05= 90.12 days
800,974,912/ (17,959,489,496/365) =
16.28 days
20,695,259,012/23,734,742,933 = 0.87 times
2014 11,727,992,671/2,345,389,488 = 5 times
365 / 5= 73 days 757,757,419/ (20,910,773,826/365) =
13.23 days
24,262,297,324/26,549,534,878 = 0.91 times
Debt. Ratio
Renata Ltd.
Year Debt. Ratio = Total liabilities/Total assets
Debt. To equity ratio = Total liabilities/Common stock equity
Times interest earned ratio = Operating profit/Interest
2011 3,732,993,864/7,691,601,900 = 48.53%
3,732,993,864/3,958,608,036 = 94.30%
1,087,719,131/215,315,416 = 5.05 times
2012 4,682,598,223/9,753,077,971 = 48.01%
4,682,598,223/5,070,479,748 = 92.35%
1,237,926,366/370,881,897 = 3.33 times
16
2013 5,266,051,481/12,714,843,610 = 41.40%
5,266,051,481/6,295,114,611 = 83.65%
2,429,127,137/449,500,132 = 5.40 times
2014 5,214,178,551/14,493,568,729 = 35.98%
5,214,178,551/7,750,713,063 = 67.27%
2,910,940,303/463,471,214 = 6.28 times
Square Pharmaceuticals Ltd.
Year Debt. Ratio = Total liabilities/Total assets
Debt. To equity ratio = Total liabilities/Common stock equity
Times interest earned ratio = Operating profit/Interest
2011 5,626,700,666/19,444,409,654 =28.93%
5,626,700,666/13,817,708,990 = 40.72%
3,585,489,925/170,737,615 = 21 times
2012 5,186,900,507 / 21,453,784,762 = 24.17%
5,186,900,507/ 19,120,019,851 = 27.12%
1,783,055,287/433,581,036 = 4.11times
2013 4,681,851,115/23,734,742,933 = 19%
4,681,851,115/19,052,891,818 = 24.5%
3,956,139,219/325,281,016 = 12.16 times
2014 4,272,018,250/26,549,534,878 = 16%
4,272,018,250/22,277,516,628 = 19%
5,008,816,403/169,180,826 = 29.6 times
Profitability Ratios
Year Gross profit
margin = Gross
profit/Sales
Operating profit margin = Operating profit/Sales
Net profit margin = Earnings
available for common
stockholders/Sales
Earnings per share = Net income/Com
mon stock outstanding
Return on assets = Net income/Tota
l assets
Return on equity = Net
income/Common stock equity
2011 3,420,283,279/6,519,639,234
= 52.46%
1,708,135,175/6,519,639,23
4 = 26.19%
1,438,836,938/6,519,639,234 =
22.07%
1,438,836,938/29,888,594.47 =
48.14%
1,438,836,938/7,691,601,900
= 18.71%
1,438,836,938/3,958,608,036 =
36.35%2012 4,051,958,65
9/7,671,572,303 = 52.82%
2,161,099,398/7,671,572,30
3 = 28.17%
1,237,926,366/7,671,572,303 =
16.14%
1,237,926,366/28243813.96 =
43.83%
1,237,926,366/9,753,077,971
= 12.69%
1,237,926,366/5,070,479,748 =
24.41%17
2013 4,670,630,720/8,757,405,748
= 53.33%
2,429,127,137/8,757,405,748
= 27.74%
1,390,164,527/8,757,405,748 = 15.87%
1,390,164,527/44,132,207.21 =
31.50%
1,390,164,527/12,714,843,610 =
10.93%
1,391,064,527/6,295,114,611 = 22.09%
2014 5,688,309,854/11,107,281,260
= 51.21%
2,910,940,303/11,107,281,260
= 26.21%
1,710,862,526/11,107,281,260 = 15.40%
1,710,862,526/44,128,514.99 =
38.77%
1,710,862,526/14,493,568,729 =
11.80%
1,710,862,526/7,750,713,063 = 22.07%
Renata Ltd.
Square Pharmaceuticals Ltd.
Year Gross profit
margin = Gross
profit/Sales
Operating profit margin = Operating profit/Sales
Net profit margin = Earnings
available for common
stockholders/Sales
Earnings per share = Net income/Com
mon stock outstanding
Return on assets = Net income/Tota
l assets
Return on equity = Net
income/Common stock equity
2011 5,767,763,459/ 15,576,487,53
6=37.02%
2,751,605,397/15,576,487,536 = 17.70%
2,532,054,550 /15,576,487,536
=16.30%
2,532,054,550/264,834,760 =
9.56%
2,532,054,550 /19,444,409,654
=13.02%
2,532,054,550 / 13,817,708,990=
18.32%2012 6,887,171,623/
18,592,856,236 = 37.04%
6,386,171,623/18,592,856,236
= 34.34%
3,037,696,965/18,592,856,236 = 16.34%
2,897,710,641/264,834,760 =
10.94%
2,897,710,641/24,376,715,644 =
11.88%
2897710641/19120019851 =
15.15%2013 7,825,814,319/
20,695,259,012 = 37.81%
3,956,139,219/20,695,259,012
= 19.10%
3,419,785,256/20,695,259,012 = 16.5%
3,419,785,256/409,065,222 = 8.36%
3,419,785,256/23,734,742,933 =
14.40%
3,419,785,256/19,052,891,818 = 17.94%
2014 9,182,781,155/24,262,297,324
= 37.84%
5,008,816,403/24,262,297,324
= 20.60%
4,031,811,268/24,262,297,324 = 16.6%
4,031,811,268/567,860,742 = 7.10%
4,031,811,268/26,549,534,878 =
15.18%
4,031,811,268/22,277,516,628 = 18.09%
Market Ratios
Renata Ltd.
Year Price/Earnings ratio = Market
price per share of common
stock/Earnings per share
Book value per share = Common stock
equity/Number of shares of common stock outstanding
Market book ratio = Market price per share of common
stock/Book value per share of common stock
2011 1205/38.51 = 31.29 3,958,608,036/37,362,683.41 = 105.95
1205/105.95 = 11.37
2012 739.50/10.94 = 67.59 5,070,479,748/28,243,813.96 = 179.53
739.50/179.53 = 4.12
2013 722/31.50 = 22.92 629,511,461/44,132,207.21 = 142.64
722/142.64 = 5.06
2014 984/38.77 = 25.38 7,750,713,063/44,128,514.99 984/175.64 = 5.60
18
= 175.64
Square Pharmaceuticals Ltd.
Year Price/Earnings ratio = Market
price per share of common
stock/Earnings per share
Book value per share = Common stock
equity/Number of shares of common stock
outstanding
Market book ratio = Market price per share of common
stock/Book value per share of common
stock2011 327.2/9.56 = 34.23 13,817,708,990/264,834,760
= 52.17327.2/52.17 = 6.27
2012 237.30/10.94 = 21.69 19,120,019,851/264,834,760 = 72.19
237.30/72.19 = 3.29
2013 178.60/8.36 = 21.36 19,052,891,818/481,659,895.2 = 39.56
178.60/39.56 = 4.51
2014 147.85/7.10 = 20.82 22,277,516,628/482,274,075.1 = 46.19
147.85/46.19 = 3.20
19